LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC System Could Transform Infectious Disease Management

By LabMedica International staff writers
Posted on 27 May 2022
Print article
Image: SAMBA II is a real game changer in infectious disease management (Photo courtesy of DRW)
Image: SAMBA II is a real game changer in infectious disease management (Photo courtesy of DRW)

A new platform supports rapid, efficient and accurate diagnosis of multiple infectious diseases, aiding clinical decision-making, and enabling improved, timely access to healthcare for all.

DRW’s (Diagnostics for the Real World, Cambridge, UK) SAMBA II is a robust, simple-to-use system offers a complete end-to-end process, delivering fast results and reducing the typical 1-2 day wait from centralized laboratory tests. The SAMBA II system delivers a true point-of-care system, from sample extraction, through to isothermal nucleic acid amplification, patented lateral flow detection and automated interpretation of results.

SAMBA II is a real game changer in infectious disease management. It is fully automated, performing sample preparation, extraction, amplification and detection: a true sample in – result out system. With SAMBA II, high-tech diagnostic and treatment monitoring assays become easy to perform and require minimal training. While-you-wait results enable test and treat facilities, enhancing the way diseases are managed. Safe and easy to use, the uniquely shaped ready-to use cartridges are easy to load and include all consumables. The visual results are automatically analyzed by the integrated camera to ensure consistent and accurate interpretation, with results presented and stored on the connected tablet. SAMBA II delivers innovative assays in an easy-to-use and accessible platform for the diagnosis and treatment monitoring of infectious disease at the point of care, including HIV, SARS-CoV-2, hepatitis B and C, and influenza A and B.

The SAMBA II system is comprised of the assay module, where the test is performed, and the tablet module, which controls the assay module and displays the test results. Each tablet module can control up to four assay modules, allowing flexibility and scalability at sites using SAMBA II. SAMBA II is a connected platform. The tablet module controls the assay module and receives all results via Bluetooth. The tablet module can send results to the Bluetooth printer, or via SMS, mobile Internet or Wi-Fi to a backup tablet or a tablet in a remote clinic who send their samples to be tested with SAMBA II. The tablet module can also send test results in a standard format to a laboratory information system (LIS), to a Ministry of Health service or to the SAMBA dashboard. Test results can also be downloaded directly from the tablet via USB. With SAMBA II, test results can be sent to those that need them.

Related Links:
DRW 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.